On June 1, 2026 Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported positive overall survival and safety results from a pooled analysis of three prospective Phase I/II clinical studies evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The results were presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pancreatic cancer remains one of the most lethal of all solid tumors, with a five-year survival rate of less than 10% and survival often measured in only months for patients with advanced disease. Treatment options are particularly limited for patients who are ineligible for chemotherapy or who have progressed through one or more lines of systemic therapy, where historical survival is consistently poor and few effective interventions exist.
The pooled, ad-hoc analysis combined safety and efficacy data from three studies, conducted at the Jewish General Hospital, at the Centre Hospitalier de l’Université de Montréal (CHUM) in Montreal, Canada, and at the Hadassah Medical Center in Jerusalem, Israel. The analysis included all patients who received the intended Alpha DaRT treatment, with a range of patients having undergone varying lines of prior chemotherapy. Survival was analyzed using the Kaplan-Meier method and assessed by disease stage (locally advanced versus metastatic) and by number of prior chemotherapy lines (zero, one, or two).
Overall Survival Results
Note: Caution should be exercised in comparing results from unrelated clinical studies due to differences in study designs, patient populations and other relevant factors.
Alpha DaRT-treated patients who had received one prior line of chemotherapy achieved a median overall survival of 17.0 months in metastatic disease and 13.8 months in locally advanced disease, from the date of initiation of the prior line of chemotherapy. Alpha DaRT as second-line therapy, measured from study enrollment, achieved an mOS of 11.2 months in metastatic patients, while in the published literature, mOS for metastatic patients with second-line chemotherapy is reported to be ~ 4-6 months (from initiation of second-line chemotherapy), and for the locally advanced patients, achieved an mOS of 11.1 months, vs. ~9 months.
Alpha DaRT-treated patients who had received two prior lines of chemotherapy – a heavily pretreated population for whom there is no established standard of care – achieved a median overall survival of 17.1 months in locally advanced disease and 11.3 months in metastatic disease, from the date of initiation of the second-line chemotherapy. Alpha DaRT as third-line therapy, measured from study enrollment, achieved an mOS of 7.9 months in metastatic patients, and for the locally advanced patients, achieved an mOS of 8.8 months, while in the published literature, mOS for patients with third-line chemotherapy is reported to be ~ 4-7 months (from the initiation of third-line chemotherapy).
Patients who were treated with Alpha DaRT and who had not received any prior chemotherapy demonstrated mOS of 7.1 months from diagnosis in both locally advanced and metastatic diseases, which includes mOS of 6.3 and 5.8 months, from trial enrollment, for locally advanced and metastatic patients, respectively.
Safety Results
Alpha DaRT was observed to have a favorable safety profile. Treatment-associated adverse events were observed in 36% of subjects, and Grade ≥ 3 adverse events were observed in 9% of subjects, including biliary obstruction, abdominal pain, fever, liver enzyme imbalance, and bacteremia. Importantly, there were no treatment-related deaths, all Grade ≥ 3 adverse events resolved, and no chronic adverse events were observed. This safety profile is especially relevant in advanced pancreatic cancer, where patients are often frail and where the cumulative toxicity of ongoing systemic therapy can significantly compromise quality of life.
A key differentiator of Alpha DaRT is its potential as a one-time, minimally invasive intratumoral administration, as compared to continuous oral or intravenous therapy.
Uzi Sofer, CEO of Alpha Tau, stated: "I have always believed deeply in the potential of Alpha DaRT to be highly efficacious, but I say proudly that these results exceeded even my own expectations, and are an outstanding extension of the interim results in these first-in-human trials that we observed last year. To see this level of survival, achieved with a one-time treatment and without chronic side effects, in patients who today have so little to turn to, strengthens our resolve to bring Alpha DaRT to as many of these patients as possible, as quickly as we responsibly can. These first-in-human results are fantastic, and they demonstrate the potential of Alpha DaRT as a monotherapy, even when compared to standard-of-care chemotherapies. And now we are even more excited about the treatment design of our U.S. IMPACT trial. In treating pancreatic cancer, our goal is not to replace chemotherapy or other next-generation systemic therapies, our goal is to explore whether Alpha DaRT can serve as a compelling focused local therapy and add a concurrent therapeutic boost without exacerbating the harsh systemic side effects of standard chemotherapy regimens. We are excited about the advent of new systemic therapy options for pancreatic cancer patients, and given the safety profile observed thus far for Alpha DaRT, we believe there is compelling rationale for exploring further combination trials in the future with new systemic therapies as they become standard-of-care. Pancreatic cancer is one of the cruelest diagnoses, and these patients deserve therapies that deliver not only meaningful efficacy, but also a safety profile and treatment experience that respect their quality of life and fit into their journey rather than dominate it."
Corey Miller, MD, MSc, Director of Therapeutic Endoscopy of the Division of Gastroenterology at the Jewish General Hospital, Assistant Professor of Medicine at McGill University, and Principal Investigator in Canada, commented: "As the first physician in the world to deliver Alpha DaRT into the pancreas using an endoscopic ultrasound-guided approach, seeing these results is genuinely extraordinary for me. I treated some of the very first patients in this program, and that trajectory, from the early procedures all the way through to receiving the survival outcome data with no observed chronic toxicity, has been truly fantastic to witness and a privilege to be a part of."
Robert Den, MD, Chief Medical Officer of Alpha Tau, added: "These pooled survival and safety data provide extremely encouraging reinforcement of our clinical strategy which we are moving decisively to execute across a broad and increasingly global clinical program. Historically, local therapy has not played a big role in treating non-resectable pancreatic cancer due to poor clinical trial results secondary to limitations on dose escalation in the pancreas in light of the sensitive organs in the area, as well as the inability to dose chemotherapy at systemic therapy levels concurrently with local therapy. We seek to make local therapy an integral part of the treatment of pancreatic cancer, without compromising the ability to deliver systemic therapy concurrently. Our flagship multicenter IMPACT trial in the United States continues to advance, evaluating Alpha DaRT in combination with chemotherapy in patients with newly diagnosed unresectable pancreatic cancer. The ACAPELLA trial in France, evaluating Alpha DaRT alongside capecitabine in patients with locally advanced pancreatic cancer, is underway following the treatment of its first patient. And our work at the prestigious University of Verona’s Pancreas Institute is extending the program to include a percutaneous delivery approach, broadening the range of patients who may be able to access this therapy. Together, these studies reflect a deliberate, methodical effort to generate the rigorous evidence needed to bring Alpha DaRT to patients with one of the most significant unmet needs in oncology."
About the Studies
The analysis presented is a pooled ad-hoc analysis of three prospective Phase I/II clinical studies conducted at centers in Canada and Israel, evaluating EUS-guided intratumoral Alpha DaRT in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma across varying lines of prior chemotherapy. The analysis included all cases that received the intended treatment. Survival analyses used the Kaplan-Meier method, measured from the time of enrollment or from the initiation of the previous line of chemotherapy, to death, and were analyzed by disease stage and number of prior chemotherapy lines (zero, one, or two).
About Alpha DaRT
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
(Press release, Alpha Tau Medical, JUN 1, 2026, View Source [SID1234666294])